United Therapeutics Corporation (Nasdaq: UTHR) reported record financial results for the second quarter ending June 30, 2025. The company achieved a 12 percent year-over-year increase in total revenues, reaching $798.6 million compared to $714.9 million in the same period of 2024. Significant growth was observed in key products, with Tyvaso DPI sales increasing by 22 percent to $315.2 million and Nebulized Tyvaso sales rising by 10 percent to $154.4 million. Orenitram and Unituxin also saw notable sales increases of 16 percent and 13 percent, respectively. Net income for the quarter was reported at $309.5 million, an 11 percent rise from the prior year's $278.1 million. Earnings per basic share increased to $6.86 from $6.26, while earnings per diluted share grew from $5.85 to $6.41, marking a 10 percent improvement. United Therapeutics highlighted the strength of their commercial business as a key driver for these results. The company's effective income tax rate for the quarter was 24 percent, slightly up from 22 percent in the same period of 2024, primarily due to a decrease in excess tax benefits from share-based compensation.